about
Metastatic disease from uveal melanoma: treatment options and future prospectsCross-species models of human melanomaTargeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitorsA novel classification of lung cancer into molecular subtypesActionable gene expression-based patient stratification for molecular targeted therapy in hepatocellular carcinomaMining gene expression signature for the detection of pre-malignant melanocytes and early melanomas with risk for metastasisSilencing of diphthamide synthesis 3 (Dph3) reduces metastasis of murine melanoma.Coordinate autophagy and mTOR pathway inhibition enhances cell death in melanoma.Melanoma genotypes and phenotypes get personal.Biomarkers as key contributors in treating malignant melanoma metastases.Cisplatin fails to induce puma mediated apoptosis in mucosal melanomasDelving into somatic variation in sporadic melanoma.The CASC15 Long Intergenic Noncoding RNA Locus Is Involved in Melanoma Progression and Phenotype SwitchingIdentification of a novel role of RING finger protein 11 promoting the metastasis of murine melanoma cells.The kin17 Protein in Murine Melanoma Cells.Caffeic acid phenethyl ester suppresses melanoma tumor growth by inhibiting PI3K/AKT/XIAP pathway.NRAS and EPHB6 mutation rates differ in metastatic melanomas of patients in the North Island versus South Island of New Zealand.A DNA vaccine targeting p42.3 induces protective antitumor immunity via eliciting cytotoxic CD8+T lymphocytes in a murine melanoma model.miRNAs and Melanoma: How Are They Connected?Modelling melanoma in mice.Reviewing the somatic genetics of melanoma: from current to future analytical approaches.Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations.Developing melanoma therapeutics: overview and update.Rapid learning for precision oncology.Lysosomes and unfolded protein response, determinants of differential resistance of melanoma cells to vinca alkaloids.NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics.MTSS1 is a metastasis driver in a subset of human melanomas.Mouse models of UV-induced melanoma: genetics, pathology, and clinical relevance.Targeting p53 in melanoma.Differential involvement of glutathione S-transferase mu 1 and multidrug resistance protein 1 in melanoma acquired resistance to vinca alkaloids.Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells.Identification of HRAS mutations and absence of GNAQ or GNA11 mutations in deep penetrating nevi.Sinonasal mucosal melanoma: Molecular profile and therapeutic implications from a series of 32 cases.
P2860
Q26738377-366AF3C6-8F16-486C-A641-7002EFB924BCQ26782090-F53BEFDE-8584-4000-9872-B294D425E4FFQ26827580-A59F5FC8-26E4-4608-9174-A0EA880E5ED4Q28731874-152A4152-E482-4E0D-BF3A-DDF838707182Q31119684-89B4C1E8-E9CC-481E-8C69-1F7DCFD9D3D9Q34416127-50EF1E61-3CF8-48FD-B84D-1608C49FD633Q34490844-09B96377-9638-4B8B-9331-E44B672E4287Q34576062-586958B4-D181-4460-82E2-0C5D108FE5ABQ34788817-9CC200C7-959D-406B-865F-EA5E2FAFFE05Q35550888-353825A7-E8CA-403D-9B97-9079C6AD4F24Q35833179-AAD2E8BC-65FE-4099-9349-8DD538E2002EQ36030770-64D23C3B-B6D3-432B-B8D1-15713CA8EEAFQ36054438-033A740D-A2F1-4501-AD58-78E06A397284Q36225861-CD647EE3-9EBA-4F90-9DCC-BB4B627DE233Q36324835-9EF3F39A-0618-40D9-B396-C3F1FDC23DDEQ37151630-03A21E74-C5DE-4AB2-92A4-166605BEA58FQ37520141-B65EDABE-C092-4F17-B7D2-10BBEAF09F5DQ37530511-C3D24BDC-1703-40A7-9F64-F6649942DB72Q37921096-5F4CD0B5-487B-46CD-B4A0-9FB446D05587Q37943839-C6C5B18C-5803-4E8A-B341-8FF56F20FB23Q37976140-7E9DE391-2028-4BA9-B6ED-1EB4C39E6747Q38041729-C1BB3E95-6B53-4954-AD8A-48C514349A22Q38081406-8A39AD07-188C-4812-B44A-07CB5DC0EE65Q38180318-8A61E465-1D2B-42E7-AE7E-D0E6F83D6711Q38918570-58124F4D-4E72-4942-BD59-0F52E2EC1C5BQ38925098-EE8C1BB4-328D-4C87-9CA3-6D847E51401DQ39015094-2222ABA0-2F10-4F87-8108-E28E36F41E25Q39090543-A8B9FFD5-7A0D-4872-80F3-D8AAFEEC3727Q42751623-07147435-0CDF-4114-BA60-C795BB4BC14EQ46207470-7BDDC732-ABD5-4C2A-83CB-1F03CF2B04CBQ47227422-99F737CC-A5BE-4D53-8457-DC8F411B1B75Q50235397-DB67B838-D706-4C9A-ADF6-9F6E40DB99AEQ54497681-63F9840E-C2F5-46D4-B78F-43025DC1056D
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A melanoma molecular disease model
@ast
A melanoma molecular disease model
@en
A melanoma molecular disease model
@nl
type
label
A melanoma molecular disease model
@ast
A melanoma molecular disease model
@en
A melanoma molecular disease model
@nl
prefLabel
A melanoma molecular disease model
@ast
A melanoma molecular disease model
@en
A melanoma molecular disease model
@nl
P2093
P2860
P3181
P1433
P1476
A melanoma molecular disease model
@en
P2093
David E Fisher
Jay M Tenenbaum
Jeff Shrager
Michael D Travers
Smruti J Vidwans
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0018257
P407
P577
2011-03-30T00:00:00Z